久久亚洲国产成人影院-久久亚洲国产的中文-久久亚洲国产高清-久久亚洲国产精品-亚洲图片偷拍自拍-亚洲图色视频

Global EditionASIA 中文雙語Fran?ais
World
Home / World / China-US

New medicine for prostate cancer available in China

chinadaily.com.cn | Updated: 2019-11-28 16:49
Share
Share - WeChat

New medicine to treat patients with non-metastatic castration-resistant prostate cancer (nmCRPC) is available in China to save those at high risk of developing metastases.

The Xian Janssen Pharmaceutical Ltd announced on Wednesday that ERLEADA (apalutamide) was put on the market in China after being granted by the China National Medical Products Administration (NMPA) in September, recognizing the urgent unmet need for patients with nmCRPC who currently have few treatment options.

ERLEADA is an androgen receptor inhibitor that works by preventing androgen from binding to the androgen receptor. It has been shown to delay the time to distant metastasis. Treatment with ERLEADA has also shown to result in the control of Prostate-Specific Antigen (PSA) levels, which is an important indicator during the early treatment and prognosis of patients with prostate cancer.

According to Professor Zhou Liqun, Head of Urology Department in Peking University First Hospital, the five year survival rate for advanced mCRPC patients is only 3% before the new method of endocrine treatment. "This rate increased to only 30% even with new treatment. So it is urgent to postpone progression and to maintain quality of life for patients living with nmCRPC and the approval of ERLEADA presents a new treatment option that can potentially addres this treatment.

The incidence rate of prostate cancer in China has increased and become one of the top five of the most common male cancers in the country over the past decade. The androgen-deprivation therapy (ADT) is the current standard of care for nmCRPC. However, if after initial sustained treatment with ADT, the cancer cells continue to progress without distant metastasis, patients will enter a stage called nmCRPC. Without interventions, 90% of patients with nmCRPC will eventually develop bone metastases, which can lead to pain, fractures and spinal cord compression.

According to data from a clinical study, ERLEADA reduced the risk of advanced metastasis or death by 72% and increased median metastasis-free survival by over two years among patients with nmCRPC who are undergoing continuous ADT treatment.

Professor Wang Jianye, Dean of Beijing Hospital and Director of National Center of Gerontology, said "In recent years, urology and oncology doctors are working on new NM-CRPC treatment and medicine. ERLEADA optimizes the standard NM-CRPC treatment in China and provides quality time for patients and their families."

"As one of the leading pharmaceutical companies in China, Xian Janssen has been dedicated to helping patients with prostate cancer in China. We recognize the varied needs of patients across all stages of prostate cancer, which require collaborative efforts from government, society and the healthcare industry to address. To help patients with prostate cancer receive better treatment, we are committed to exploring the full potential of our solutions in addressing unmet treatment needs across all stages of disease progression," said Asgar Rangoonwala, President of Xian Janssen.

ERLEADA is now available in major Chinese cities including Beijing, Shanghai, Guangzhou and Tianjin. Xian Janssen is supporting the China Primary Healthcare Foundation to launch a Patient Access Program that helps low-income patients in China access treatment with ERLEADA.

Most Viewed in 24 Hours
Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
主站蜘蛛池模板: 欧美日韩亚洲国内综合网俺 | 99在线精品视频免费观里 | 台湾黄三级高清在线观看播放 | 韩日毛片 | 日韩视频在线观看一区 | 一区二区三区网站在线免费线观看 | dvd8090cnm欧美大片 | 久久国产亚洲欧美日韩精品 | 久久久9视频在线观看 | 18在线观看国内精品视频 | 美女视频永久黄网站在线观看 | 欧美久久久久久久一区二区三区 | 亚洲高清综合 | 中国一级毛片在线观看 | 免费午夜扒丝袜www在线看 | 久久欧美精品欧美九久欧美 | 日本免费大黄在线观看 | 亚洲综合一区二区不卡 | 亚洲精品人成网线在线 | 欧美亚洲国产精品 | 日本精品久久久久中文字幕 1 | 国产免费一区二区三区在线观看 | 一级片免费观看 | 国产成人综合日韩精品婷婷九月 | 午夜在线亚洲 | 亚洲精品综合欧美一区二区三区 | 91探花福利精品国产自产在线 | 亚欧成人毛片一区二区三区四区 | 国产精品美女一级在线观看 | 欧美 日韩 国产 在线 | 亚洲国产精品区 | 日韩手机看片福利精品 | 中文字幕最新中文字幕中文字幕 | 精品国产成人a区在线观看 精品国产成人a在线观看 | 国产成人丝袜网站在线观看 | 国产在线乱子伦一区二区 | 97在线视频网站 | 欧美成人一级毛片 | 色屁屁一区二区三区视频国产 | 久久久久久久久免费影院 | 天天夜夜久久 |